Cochrane · systematic review · CD010139
Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive pulmonary disease
Geake, JB, Dabscheck, EJ, Wood‐Baker, R, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 58.3%High 5 · 41.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Indacaterol versus placebo
Population: people with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
End‐of‐study trough FEV1 mL Indacaterol vs placebo | no estimate extracted | 10 studies · 5001 participants | High |
Number of participants with a clinically significant improvement in QOL SGRQ Indacaterol vs placebo | OR 1.64 | 9 studies · 4906 participants | High |
Number of participants with clinically significant improvement in dyspnoea TDI Indacaterol vs placebo | OR 1.96 [1.73, 2.22] | 8 studies · 4577 participants | High |
Number of participants experiencing 1 or more exacerbations Indacaterol vs placebo | OR 0.81 [0.7, 0.94] | 7 studies · 4807 participants | High |
Serious adverse events Indacaterol vs placebo | OR 1 [0.82, 1.23] | 9 studies · 6065 participants | Moderate |
Mortality Indacaterol vs placebo | OR 0.42 [0.16, 1.08] | 9 studies · 5694 participants | Moderate |
Indacaterol versus twice‐daily long‐acting beta2‐agonists for chronic obstructive pulmonary disease
Population: patients with chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
End‐of‐study trough FEV1 mL Indacaterol vs twice‐daily long‐acting beta2‐agonists | no estimate extracted | 4 studies · 2708 participants | High |
Number of participants with a clinically significant improvement in quality of life SGRQ Indacaterol vs twice‐daily long‐acting beta2‐agonists | OR 1.07 [0.87, 1.32] | 2 studies · 1520 participants | Moderate |
Number of participants with a clinically significant improvement in dyspnoea TDI Indacaterol vs twice‐daily long‐acting beta2‐agonists | OR 1.11 [0.94, 1.32] | 3 studies · 2536 participants | Moderate |
Number of participants experiencing at least 1 exacerbation Exacerbations Indacaterol vs twice‐daily long‐acting beta2‐agonists | OR 1.07 [0.86, 1.33] | 2 studies · 1869 participants | Moderate |
Serious adverse events Adverse events Indacaterol vs twice‐daily long‐acting beta2‐agonists | OR 1.02 [0.79, 1.32] | 4 studies · 3266 participants | Moderate |
Mortality Deaths Indacaterol vs twice‐daily long‐acting beta2‐agonists | OR 1 [0.31, 3.28] | 4 studies · 3266 participants | Moderate |